SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-20-001517
Filing Date
2020-01-03
Accepted
2020-01-06 08:42:02
Documents
6
Group Members
SUMITOMO DAINIPPON PHARMA CO., LTD.SUMITOVANT BIOPHARMA LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D d854669dsc13d.htm SC 13D 117725
2 EX-1 d854669dex991.htm EX-99.1 759655
3 EX-2 d854669dex992.htm EX-99.2 227331
4 EX-3 d854669dex993.htm EX-99.3 226242
5 EX-4 d854669dex994.htm EX-99.4 42666
6 EX-5 d854669dex995.htm EX-99.5 371283
  Complete submission text file 0001193125-20-001517.txt   1746544
Mailing Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB
Business Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB 44(0)207 400 3347
Myovant Sciences Ltd. (Subject) CIK: 0001679082 (see all company filings)

IRS No.: 000000000 | State of Incorp.: CA | Fiscal Year End: 0331
Type: SC 13D | Act: 34 | File No.: 005-89732 | Film No.: 20508138
SIC: 2834 Pharmaceutical Preparations

Mailing Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Business Address 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 813-5543-5142
Sumitomo Chemical Co., Ltd. (Filed by) CIK: 0001798550 (see all company filings)

IRS No.: 980339148 | State of Incorp.: M0 | Fiscal Year End: 0331
Type: SC 13D